Desk› Healthcare› Kwality Pharmaceuticals Ltd

Kwality Pharmaceuticals Ltd

BSE 539997 KPL INE552U01010

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Filing rhythm · 60 trading days

15 filings · 5 material · busiest 2026-08-12

What it files

Analyst / Investor Meet4 Newspaper Publication2 Concall Transcript2 Board Outcome1 Results1 Investor Presentation1 Board Meeting1 General1

Filings

15 in the window

13 August 2026

Newspaper Publication

Newspaper Publication

Newspaper Publication of Unaudited Financial Results for the quarter ended June 30, 2026.

Company Update / Newspaper Publication View filing →
12 August 2026

Concall Transcript

Earnings Call Transcript

Transcript of Earnings Conference Call - Q1FY27

Company Update / Earnings Call Transcript View filing →
12 August 2026

Concall Transcript

Earnings Call Transcript

Transcript of Earnings Conference Call - Q1FY27

Company Update / Earnings Call Transcript View filing →
12 August 2026

Analyst / Investor Meet

Analyst / Investor Meet - Outcome

Outcome of Investors/Analysts Meeting held on August 10, 2026

Company Update / Analyst / Investor Meet View filing →
12 August 2026

Newspaper Publication

Newspaper Publication

Newspaper Publication of Notice of 43rd Annual General Meeting.

Company Update / Newspaper Publication View filing →
10 August 2026

Board Outcome

Board Meeting Outcome for Submission Of Standalone And Consolidated Unaudited Financial Results For The Quarter Ended On 30.06.2026 Under Regulation 33 Of The SEBI (LODR) Regulations, 2015

Submission of standalone and consolidated unaudited financial results for the quarter ended on 30.06.2026 under Regulation 33 of the SEBI (LODR) Regulations, 2015

Board Meeting / Outcome of Board Meeting View filing →
10 August 2026

Results

Submission Of Standalone And Consolidated Unaudited Financial Results For The Quarter Ended On 30.06.2026 Under Regulation 33 Of The SEBI (LODR) Regulations, 2015

Financial Results for Quarter Ended June 30, 2026.

Result / Financial Results View filing →
10 August 2026

Investor Presentation

Investor Presentation

Investor Presentation for quarter ended June 30, 2026.

Company Update / Investor Presentation View filing →
4 August 2026

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Intimation of Earnings Conference Call for Q1 FY 2026-27

Company Update / Analyst / Investor Meet View filing →
4 August 2026

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Intimation of Earnings Conference Call for Q1 FY 2026-27

Company Update / Analyst / Investor Meet View filing →
4 August 2026

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Intimation of Earnings Conference Call for Q1 FY 2026-27

Company Update / Analyst / Investor Meet View filing →
3 August 2026

Board Meeting

Board Meeting Intimation for Consideration And Approval Of Standalone & Consolidated Unaudited Financial Results For The Quarter Ended 30-06-2026.

Kwality Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve the Standalone and ....

Board Meeting / Board Meeting View filing →
24 July 2026

General

Disclosure Under Regulation 30 Of SEBI LODR

Kwality Pharmaceuticals receives CDSCO Nod to Initiate Preclinical Pilot Batches of Pembroluzimab

Company Update / General View filing →
13 July 2026

Compliance Certificate

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30-06-2026.

Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
29 June 2026

Trading Window

Closure of Trading Window

Intimation of Closure of Trading Window

Insider Trading / SAST / Closure of Trading Window View filing →